This acquisition will allow barda to invest project bioshield funds for late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50126C00010
- Awardee
-
Kaleo, Inc. UEI LBM4GLJNDK31
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $96,058,494
Award facts
- Opportunity
-
- 2-PAM Autoinjectors Project Bioshield Pre-Solicitation · 75A50126R00002 · Posted Jun 2, 2026
- Contract value 28% obligated
-
- $96,058,494.00 Current, with exercised options
- $340,910,795.00 Potential, with all options
- Completion date 1% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Glen Allen, VA 23060, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a $340.9 million definitive contract to Kaleo, Inc. for late-stage clinical development, regulatory approval, and procurement of 2-PAM autoinjectors as a drug/device combination product to treat organophosphate poisoning, including nerve agents, on September 30, 2026.
The contract funds BARDA investment under the Project BioShield Act for adult and pediatric formulations intended for the Strategic National Stockpile CHEMPACK Program. Pricing is cost plus fixed fee. Place of performance is Glen Allen, VA. The ultimate completion date is December 31, 2034. The originating pre-solicitation, posted June 2, 2026 with responses due June 16, 2026, described clinical development through regulatory approval and subsequent device procurement under NAICS 541714 (biotechnology research and development). No set-aside was used.
Description
This acquisition will allow barda to invest project bioshield funds for late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agent
Quick answers
Who was awarded contract 75A50126C00010?
75A50126C00010 was awarded to Kaleo, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2026.
How much is contract 75A50126C00010 worth?
The government has obligated $96,058,494 on 75A50126C00010. Its potential value, with all options, is $340,910,795.
Was contract 75A50126C00010 competed?
The extent of competition for 75A50126C00010 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award